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PR-39 is an endogenous antimicrobial peptide isolated from pig
small intestines (Agerberth et al, 1991; Storici and Zanetti, 1993);
it has been recognized as an important mediator of innate immu-
nity against microbes (Boman, 1995; Martin et al, 1995). Among
antimicrobial peptides, PR-39 has been classified into a proline-
and arginine-rich family, which also includes Bac5 and Bac7 of
bovine neutrophils (Storici et al, 1994). Most antimicrobial
peptides interact with bacterial membranes and cause lysis, but
PR-39 kills bacteria by a non-pore-forming mechanism, presum-
ably by inhibiting DNA and protein synthesis (Boman et al, 1993).
To date, there is no other antimicrobial peptide of animal origin
known to have a similar mechanism of action (Agerberth et al,
1996). The pre-proform of PR-39 consists of three parts: a signal
sequence (preregion) for targeting to the endoplasmic reticulum, a
proregion which belongs to the cathepsin L inhibitor (cathelin)
family, and a mature region composed of 49% proline and 24%
arginine. Recently, new functions of PR-39 have been reported
that PR-39 inhibits phagocyte NADPH oxidase activity of pig
neutrophils by binding to Src homology 3 (SH3) domains of
p47phox (Shi et al, 1996), and that PR-39 binds to and affects a
SH3-containing signal transduction protein, P130Cas (Chan and
Gallo, 1998). Other proline-rich peptides bind various intracellular
SH3 domain-containing proteins, so that proline-rich motif of PR-
39 may have a number of functions affecting a variety of intra-
cellular signalling pathways and cytoskeletal proteins, in a range
of organisms from yeast to man (Yu et al, 1994; Pawson, 1995). In
an attempt to isolate the human counterpart of PR-39, Agerberth et
al found FALL-39, the proregion of which belonged to the cathelin
family, while its mature region did not contain proline-rich
sequences (Agerberth et al, 1995). Thus, the proline-rich region of
PR-39 is thought to be essential for all its functions. However, in
the human counterpart containing proline, arginine sequences have
not yet been found.
Independently, while trying to isolate factors for promoting
wound healing by examinig the ability to induce syndecan-1
expression in vitro, Gallo et al (1994) found a 4.7 kDa protein
from pig wound fluids. They initiated their work because synde-
cans are cell surface proteoglycans involving cell-to-matrix inter-
actions and growth factors binding in mouse mesenchymal cells
and are essential for wound healing (Gallo et al, 1994). By amino
acid analysis, it was found that this syndecan-inducing factor was
identical to PR-39.
Moreover, we found that the expression of syndecan-1 was
reduced in human hepatocellular carcinomas (HCC) with high
metastatic potential and speculated that syndecan-1 played an
important role in inhibition of invasion and metastasis (Matsumoto
et al, 1997). Our speculation was supported by Liebersbach’s
paper that the transfection of syndecan-1 gene inhibited invasion
into type I collagen by the cell binding in human B lymphoid cell
line (Liebersbach and Sanderson, 1994). Like most malignancies,
the leading cause of death from this carcinoma still results from
intrahepatic and/or distant metastasis, even though many advanced
therapeutic procedures, both surgical and interventional, have
been made. Therefore, it is assumed that a modification of this
process might become a new strategy for inhibiting the invasion
and metastasis of tumour cells.
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Summary PR-39 is an endogenous proline-rich antimicrobial peptide which induces the synthesis of syndecan-1, a transmembrane heparan
sulphate proteoglycan involved in cell-to-matrix interactions and wound healing. Previously, we revealed that the expression of syndecan-1 was
reduced in human hepatocellular carcinomas with high metastatic potential and speculated that syndecan-1 played an important role in inhibition
of invasion and metastasis. It is assumed that a modification of this process with PR-39 and syndecan-1 may result in a new strategy by which it
can inhibit the invasion and metastasis. Therefore, we transduced a gene of PR-39 into human hepatocellular carcinoma cell line HLF, which
shows a low expression of syndecan-1 and a high in vitro invasive activity, and examined whether this procedure could reduce the invasive activity
of tumour cells. In two transfectants with PR-39 gene, the syndecan-1 expression was induced and the invasive activity in type I collagen-coated
chamber was inhibited. Moreover, these transfectants showed the suppression of motile activity assayed by phagokinetic tracks in addition to the
disorganization of actin filaments observed by a confocal imaging system. In contrast, five transfectants with syndecan-1 gene in the HLF cells
revealed suppression of invasive activity but did not alter the motile activity and actin structures of the cell. These results suggest that PR-39 has
functions involved in the suppression of motile activity and alteration of actin structure on human hepatocellular carcinoma cells in addition to the
suppression of invasive activity which might result from the induction of syndecan-1 expression. © 1999 Cancer Research Campaign
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gene transfection into human HCC cells could suppress the inva-
sive activity, because PR-39 may have multifunctions affecting
cell adhesion and intracellular signaling directly or indirectly. The
possibility of the PR-39 gene as a candidate for a new strategy of
gene therapy was evaluated.
MATERIALS AND METHODS
Cell culture
Human HCC cell lines, HuH-1 and HuH-2 (Huh and Utakoji,
1981) were given by Eisai Laboratory (Tsukuba, Japan), and HLE
and HLF (Doi et al, 1975) were purchased from Japanese Cancer
Research Resources Bank (Tokyo, Japan). Cells were maintained
in RPMI-1640 supplemented with 10% fetal bovine serum (FBS),
2m ML -glutamine, 100 units ml–1 penicillin and 100 mg ml–1 strep-
tomycin sulphate.
In vitro invasion assay
Invasion assay was performed by a modification of the methods of
Albini et al (1987). Artificial basement membranes of a Transwell
cell culture chamber (Costar Corp., Cambridge, MA, USA) were
prepared by coating 6.5-mm-diameter polycarbonate filters (8-mm
pore size, polyvinylpyrrolidone-free) with 25 and 150 mg of type I
collagen obtained from rat tail tendon collagen (Collaborative
Biomedical Corp., Bedford, MA, USA). The lower compartments
of blind-well invasion chambers were filled with 700 ml RPMI-
1640 supplemented with 10% FBS. Cells (1 ´ 105) suspended in a
total volume of 200 ml of invasion medium were then added to the
upper invasion chamber compartments. After 8 and 24 h of incu-
bation in a tissue culture incubator, the filters were fixed with 70%
ethanol and stained with Giemsa solution. The number of cells that
migrated through the membrane were counted in six random
microscope fields of ´ 200 magnification of the lower filter
surface.
Northern blot analysis
Twenty micrograms of total RNA per lane was electrophoretically
separated on a 1.0% agarose gel. After transfer the nylon
membrane (Hybond™-N+, Amersham Corp., Tokyo, Japan) was
prehybridized for 45 min at 65°C, hybridized for 90 min with a
32P-random primer-labelled probe using a hybridization solution
(Amersham Corp., Tokyo, Japan) and washed to a final stringency
of 65°C in 1 ´ standard saline citrate (SSC) and 0.1% sodium
dodecyl citrate (SDS). The syndecan-1 probe was a 490 bp EcoRI
fragment of mouse syndecan-1 cDNA (pMB-29, kindly provided
by Dr M Bernfield) and the syndecan-4 probe was a 370 bp EcoRI
and  BamHI fragment of human syndecan-4 cDNA (pMB-237,
kindly provided by Dr M Bernfield). Ribosomal RNA expression
was used as an internal control.
Vector construction and transfection
PR-39 fragment (nucleotide 4–539) containing a whole coding
region of pig PR-39 gene (Storici and Zanetti, 1993) was amplified
from pig small intestine mRNAs by RT-PCR (reverse transcrip-
tase-polymerase chain reaction) using a primer (5¢-GGGCT-
CAGGATTCACCAAAAGCTTTTAATGGGT-3¢) for RT and two
primers (5¢-CTCACCTGGGCACCATGGAG-3¢, 5¢-GGGTAT-
GTTATCAGCCACTC-3¢) for PCR, and ligated into pCR™II
vector (Amersham Corp., Tokyo, Japan). The PR-39 fragment in
pCR™II vector was excised with HindIII–XbaI, and ligated into
pRc/CMV expression vector (Invitrogen, San Diego, CA, USA).
Syndecan-1 fragment (nucleotide 92–1289) containing a whole
coding region of mouse syndecan-1 gene was amplified from
clone pMB-5 (kindly provided by Dr M Bernfield) (Saunders et al,
1989) by PCR using two primers (5¢-AGTAAGCTTACA-
GCCCTCGCTCGA-3¢, 5¢-CAATGTCTAGAGGACATGACCC-
AG-3¢) and ligated into pCR™II vector. The fragment was excised
with HindIII–XbaI, and ligated into pRc/CMV expression vector.
Human HCC cells, HLF, expressing a low level of syndecan-1
(Matsumoto et al, 1997), were transfected with three plasmids,
pRc/CMV vector containing pig PR-39, mouse syndecan-1 or no
insert, respectively. For transfections, 40 mg of purified plasmid
and 30 mg of Lipofectin (Gibco-BRL, Gaithersburg, MD, USA)
were added to HLF cells (approximately 70%) in 100-mm culture
dishes. After approximately 3 weeks, selection with geneticin
(1000 mg ml–1), viable colonies were subcultured using cloning
rings.
Immunoprecipitation and Western blot of PR-39
Cells were lysed in 25 mM Tris–HCl, pH 7.5, 150 mM sodium
chloride (TBS) plus 0.5% Nonidet P-40 and PR-39 was immuno-
precipitated from 1 mg of the total cell protein or 20 ml culture
medium with anti-PR-39 polyclonal antiserum, which was
produced by immunization of rabbit with 39 amino acids
oligopeptide of PR-39 in our laboratory. After washing three times
with TBS containing 0.25% Tween-20, the antibody–antigen
complexes were dissociated by heating at 100°C for 4 min in
standard Laemmli sample buffer, and the material separated on 
a 4–20% Tris–glycine gradient polyacrylamide gel (Bio-Rad
Laboratories, Hercules, CA, USA). Gels were electroblotted onto
nitrocellulose membranes (Bio-Rad Laboratories), incubated with
anti-PR-39 antiserum, horseradish-conjugated goat anti-rabbit IgG
(Seikagaku Kogyo, Tokyo, Japan), and the immune complexes
were detected by enhanced chemiluminescence (ECL) detection
system (Amersham International plc, Buckinghamshire, UK).
Western blot of syndecan-1
The extracellular domain of syndecan-1 was isolated from cells as
previously reported with slight modification (Koda et al, 1985).
The cell pellets were resuspended with 20 mM Tris-buffered saline
pH 7.4 containing 5 mM EDTA and sonicated. To release the extra-
cellular domain of syndecan-1, the whole cell extract after sonica-
tion was placed on ice for 10 min after an addition of 20 mg ml–1
bovine pancreatic trypsin (type III, Sigma Chemical Co, St Louis,
MO, USA). The reaction was stopped by adding 100 mg ml–1
soybean trypsin inhibitor (type I-S, Sigma Chemical Co, St Louis,
MO, USA). The extracellular domain was partially purified by
DEAE Sephacel (Pharmacia Biotech, Piscataway, NJ, USA) as
previously reported (Koda et al, 1985). To prepare the core protein
of the extracellular domain of syndecan-1, GAG side-chains were
removed by treatment with heparin–sulphate lyase (heparitinase,
EC 4.2.2.8, Seikagaku Kogyo, Tokyo, Japan) and chondroitin
ABC lyase (chondroitinase ABC, EC 4.2.2.4. Seikagaku Kogyo,
Tokyo, Japan) (Rapraeger et al, 1985). The extracellular domain of
syndecan-1 before removal of GAG side-chains was separated on
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GAG side-chains were separated on a 7% polyacrylamide gel
containing 2.6 M urea using a running buffer composed of 40 mM
Tris, 60 mM boric acid, 0.8 mM EDTA, 1 mM Na2SO4, 0.1% SDS,
and electrophoretically transferred to Immobilon N membrane
(Millipore, Bedford, MA, USA) as previously reported (Rapraeger
et al, 1985). The membrane was blocked with 5% dry milk, 10 mM
Tris-HCl pH 7.4, 0.15 M sodium chloride, 0.05% sodium azide for
30 min at room temperature, incubated with anti-mouse syndecan-
1 antibody, 281–2 (PharMingen, San Diego, CA, USA) at 4°C
overnight, and washed with 20 mM Tris–HCl pH 7.4, 0.15 M
sodium chloride, 0.05% Tween-20 (TBS/Tween). The membrane
was incubated for 1 h at room temperature with horseradish
peroxidase conjugated anti-rabbit IgG, washed with TBS/Tween
and visualized with ECL detection system.
Phagokinetic track motility assay
Uniform carpets of gold particles were prepared on coverslips
coated with bovine serum albumin or type I collagen (1 mg ml–1), as
described by Albrecht-Buehler (1977). Colloidal gold-coated cover-
slips were placed in 35-mm tissue culture dishes containing 2 ml
culture medium with 10% FBS, and then 2000 cells were added to
each plate. After 48 h, phagokinetic tracks were visualized using
dark-field illumination in an Olympus inverted microscope at a
magnification of 200 ´. The area cleared of gold particles by at least
ten cells selected randomly was measured. Furthermore, in order to
examine the relative contribution of syndecan-1 to inhibit motility
on Type I collagen-coated plates, cells were grown and assayed in
the presence of 30 mM sodium chlorate, which at this dose
completely prevents the sulphation of glycosaminoglycan.
Immunofluorescent analysis of syndecan-1
Cells grown on coverslips were fixed with freshly prepared 2%
paraformaldehyde in phosphate-buffered saline (PBS) for 20 min and
incubated anti-mouse syndecan-1 antibody, 281-2, or anti-human
syndecan-1 antibody, BB4 (Serotec Ltd, Oxford, UK) for 1 h. After
washing with PBS, the cells were incubated with fluorescent Cy3-
conjugated rabbit anti-rat IgG or goat anti-mouse IgG (Biological
Detection Systems Inc., Pittsburg, PA, USA), mounted on glass
slides with PermaFluor Aqueous Mountant (Lipshaw Immunon,
Pittsburg, PA, USA), and visualized using Axioscope FL microscopy
(Carl Zeiss Inc., Jena, German).
Staining of actin filament
Cells grown on coverslips were rinsed twice with a cytoskeletal
stabilizing buffer (4 M glycerol, 25 mM PIPES [pH 6.9], 1 mM
EGTA and 1 mM magnesium chloride), incubated in the same
buffer containing 0.2% Triton X-100 for 5 min at 20°C to extract
soluble proteins, and fixed for 45 min at 20°C in 3.7% formalde-
hyde in PBS. After two 10-min washes in PBS, cells were incu-
bated with rhodamine-conjugated phalloidin (Amersham Corp.,
Tokyo, Japan) diluted 1:50 in PBS containing 0.5 mg ml–1 bovine
serum albumin for 30 min. Cells were mounted with PermaFluor
Aqueous Mountant, and observed with Laser Scanning Confocal
Imaging System MRC-600 (Bio-Rad, Hertfordshire, UK).
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Figure 1 Invasive activity of human hepatocellular carcinoma cells.
Invasive activity was assayed in vitro by type I collagen (25 mg) coated 8-mm
pore size filter of the invasion chamber. The number of cells that invade the
filters after 24 h was counted in six random microscope fields of ´ 200
magnification of the lower filter surface to represent the invasive activity.
Invasive activity of both HLE (lane 1) and HLF (lane 2) cells was significantly
higher than that of HuH-1 (lane 3) and HuH-2 (lane 4). *Values for invasive
activities significantly different from HLE (lane 1) (P < 0.001). †Values for
invasive activities significantly different from HLF (lane 2) (P < 0.001)
Figure 2 Expression of transfected PR-39 and endogenous syndecan-1 and
syndecan-4 genes examined by Northern blot. (A) Northern blot analysis
using pig PR-39 cDNA probe revealed the strong hybridization signals for pig
PR-39 in two PR-39 transfectants (lanes 3 and 4) at the size of approximately
0.6 kb, but no signals were observed in parental HLF cells (lane 1) or a vector
only transfectant (lane 2). (B) Northern blot analysis using human syndecan-1
cDNA probe revealed the induction of the endogenous syndecan-1 gene
detected at the sizes of 3.4 and 2.6 kb in the two PR-39 transfectants (lanes 3
and 4) compared with the controls (lanes 1 and 2). Ribosomal RNA was used
for loading controls. Lane 1: HLF cells, lane 2: a vector-only transfectant, 
lanes 3 and 4: PR-39 transfectants (P1 and P2). (C) Northern blot analysis
using human syndecan-4 cDNA probe revealed syndecan-4 gene expression
detected at 2.6 kb was not affected by PR-39 gene transduction. Syndecan-4
was expressed highly both in PR-39 transfectants (lanes 2 and 3) and HLF
cells (lane 1). Ribosomal RNA was used for loading control. Lane 1: HLF
cells, lanes 2 and 3: PR-39 transfectants (P1 and P2)Statistical analysis
Student’s t-test or Welch’s t-test was used for statistical analysis of
invasion and motility assays.
RESULTS
Invasive activity of four human HCC cell lines
We have previously reported about mRNA and protein expres-
sions of syndecan-1 in the four human HCC cell lines (HLE, HLF,
HuH-1 and HuH-2); the expressions of syndecan-1 in HLE and
HLF cells were very low compared with those of HuH-1 and HuH-
2 cells at both mRNA and protein levels (Matsumoto et al, 1997).
In order to select an appropriate cell line, which showed a low
expression of syndecan-1 and a high invasive activity for the
experiment of PR-39 gene transfection, we examined the invasive
activities of these cell lines. A cell number that passed through
type I collagen (25 mg)-coated filter of the invasion chamber after
24 h was represented as in vitro invasive activity. We used type I
collagen rather than conventional matrigel system as an extracel-
lular matrix model because approximately 80% of human HCCs
develop from cirrhotic livers, in which 70% of total collagens were
type I (Aycock and Seyer, 1989), and syndecan-1 has a high
binding affinity to type I procollagen, but less affinity to matrigel
components such as laminin and type IV collagen (Koda et al,
1985; Elenius et al, 1990). Invasive activities of HLE and HLF
cells (lanes 1 and 2, Figure 1) were significantly higher than those
of HuH-1 and HuH-2 cells (lanes 3 and 4, Figure 1). Taking our
previous results of mRNA and protein expression of syndecan-1
with the present results of invasion assay, it was concluded that the
expression of syndecan-1 was inversely associated with the
invasive activity in human hepatocellular carcinoma cells and so,
therefore, HLF cell was an appropriate cell line to use for the
present experiment because of an endogenously low syndecan-1
expression and a high invasive activity.
Transfection with PR-39 gene into HLF cells and
induction of syndecan-1 mRNA, but not of syndecan-4
mRNA
The cDNA coding for full length of precursor (pre-pro) form of
pig PR-39 was transfected into HLF cells. Two PR-39 transfected
clones, P1 and P2 (lanes 3 and 4, Figure 2A) were obtained after
geneticin selection and showed a strong hybridization signal at
0.6 kb, the expected size for precursor PR-39 mRNA. In addition,
P1 and P2 transfectants revealed the augmentation of two spliced
forms of human syndecan-1 mRNA detected at 3.4 and 2.6 kb
(lanes 3 and 4, Figure 2B) as compared with the parental HLF and
the vector only transfectant (lanes 1 and 2, Figure 2A). On the
other hand, syndecan-4 mRNA expression was not affected by PR-
39 gene transduction; syndecan-4 was expressed highly both in
PR-39 transfectants (lanes 2 and 3, Figure 2C) and HLF cells (lane
1, Figure 2C). These data indicate that the PR-39 gene transduc-
tion to HLF cells augmented endogenous syndecan-1 mRNA but
not syndecan-4 mRNA, confirming our assumption that PR-39
gene transduction worked as a syndecan-1 inducer.
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Figure 3 PR-39 gene product in cytoplasm and culture medium of PR-39
transfectants. Immunoreactive bands of an approximately 27 kDa, a
precursor form of PR-39 (arrow), were obtained both in the cytoplasm (lane
2) and in the culture medium (lane 5). These bands were almost diminished
by antisera pre-absorbed with 100 mg of synthetic PR-39 peptide (lane 3 and
lane 6). Synthetic PR-39 peptide was detected at approximately 5 kDa (lane
7), but a mature form of PR-39 could not be detected in this condition (arrow-
head). Lane 1: cytoplasm of HLF cells, lanes 2 and 3: cytoplasm of PR-39
transfectant (P2), lane 4: medium of HLF cells, lanes 5 and 6: medium of PR-
39 transfectant (P2), lanes 3 and 6: antisera pre-absorbed with synthetic 
PR-39 peptide, lane 7: synthetic PR-39 peptide
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Figure 4 Invasive activity into type I collagen and motile activity assayed by
phagokinetic tracks of PR-39 transfectants. (A) Invasive activity was assayed
in vitro by type I collagen (150 mg)-coated 8-mm pore size filter of the invasion
chamber. A number of cells that invaded the filters after 8 h was counted in
six random microscope fields of ´200 magnification of the lower filter surface
to represent the invasive activity. Invasive activity of the two PR-39
transfectants (lanes 3 and 4) was significantly lower than that of the controls
(lanes 1 and 2). Lane 1: HLF cells, lane 2: a vector-only transfectant, lanes 3
and 4: PR-39 transfectants (P1 and P2). *Values for invasive activities
significantly different from HLF (lane 1) (P < 0.001). †Values for invasive
activities significantly different from the vector-only transfectant (lane 2) 
(P < 0.001). (B) Motile activity of PR-39 transfectants was assayed by
phagokinetic tracks. After 48 h, phagokinetic tracks were visualized using
dark-field illumination in an inverted microscope at a magnification of 200´.
The area cleared of gold particles by cells represented motile activity and
was measured. The two PR-39 transfectants showed significant reduction of
motile activity (lanes 3 and 4) compared with that of the controls (lane 1 and
lane 2). Lane 1: HLF cells, lane 2: a vector-only transfectant, lanes 3 and 4:
PR-39 transfectants (P1 and P2). *Values for motile activities significantly
different from HLF (lane 1) (P < 0.001). †Values for motile activities
significantly different from the vector-only transfectant (lane 2) (P < 0.001).PR-39 gene product in cytoplasm and culture medium
of PR-39 transfectants
To examine whether the transfectants produce PR-39 protein,
Western blot analysis was performed after immunoprecipitation
using anti-PR-39 antiserum (Figure 3). Immunoreactive bands of
an approximately 27 kDa, a precursor form of PR-39, were
obtained both in the cytoplasm (lane 2, Figure 3) and in the culture
medium (lane 5, Figure 3). These bands were almost diminished
by antisera pre-absorbed with 100 mg of synthetic PR-39 peptide
(lanes 3 and 6, Figure 3). The bands were more intense in culture
medium than in cytoplasm, suggesting that PR-39 is mainly
secreted as a precursor form. A mature form of PR-39, of which
molecular weight is approximately 5 kDa, could not be detected in
this condition.
Alteration of invasive and motile activities in PR-39
transfectants
To demonstrate the effect of PR-39 gene transduction on the
invasive character of HLF cells, an assay using a type I collagen
(150 mg)-coated filter of invasion chamber was performed. After 8 h
of incubation, the cell number that had invaded the filter was
counted in two transfectants, P1 and P2, parental cell and vector-
only transfectant, respectively. P1 and P2 transfectants (lanes 3 and
4, Figure 4A) showed a significant decrease in invasive cell number,
compared with those obtained in the parental HLF or the vector-only
transfectant (lanes 1 and 2, Figure 4a). The results of 24-h incuba-
tion were similar to those of 8-h incubation (data not shown).
As such a change of invasive activities might be caused by the
difference of motile activities in addition to cell–matrix interaction
between tumour cells and type I collagen, we then performed a
phagokinetic track assay. The area cleared of gold particles after
48 h was measured (Figure 4B). P1 and P2 transfectants (lanes 3
and 4, Figure 4B) showed significant reductions in motile activity
compared with the parental HLF cells (lane 1, Figure 4B) or the
vector-only transfected clone (lane 2, Figure 4B). These data indi-
cate that PR-39 gene transduction reduces cell motility not simply
through the cell-to-matrix interaction through the augmentation of
syndecan-1 induction.
Transfection with syndecan-1 gene into HLF cells
In order to elucidate this, the cDNA coding for full length of
murine syndecan-1 was used independently and we investigated
whether syndecan-1 gene transfection caused the same phenomena
as syndecan-1 inducer PR-39 gene. We used murine syndecan-1
gene for the transfection into the human hepatocellular carcinoma
cells because: (i) we could distinguish the product of transfected
syndecan-1 from endogenous syndecan-1 easily by using the anti-
body which specifically recognized murine syndecan-1; (ii)
murine syndecan-1 has been reported to have the same function in
PR-39 gene transduction alters invasive activity in hepatocellular carcinoma cells 397
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Figure 5 Expression of transfected mouse syndecan-1 gene examined by
Northern blot. Northern blot analysis using mouse syndecan-1 cDNA probe
revealed the strong hybridization signals in the five syndecan-1 transfectants
(lanes 5–9) at the size of approximately 1.2 kb in addition to the signals of
endogenous human syndecan-1 at the sizes of 3.4 and 2.6 kb as seen in the
parental cells and vector only transfectant (lanes 1 and 2). The signals of
transfected syndecan-1 gene at 1.2 kb were stronger than those of
augmented endogenous human syndecan-1 gene in PR-39 transfectants
(lanes 3 and 4). Ribosomal RNA was used for loading control. Lane 1: HLF
cells, lane 2: vector-only transfectant, lanes 3 and 4: PR-39 transfectants (P1
and P2), lanes 5–9: syndecan-1 transfectants (S1–S5)
Figure 6 Western blot of mouse syndecan-1 before and after removal of
heparan sulphate chains. (A) The protein samples were separated on 5%
SDS-polyacrylamide gel without removal of GAG chains. The 281–2 antibody
recognized syndecan-1 protein as a smear. (B) The protein samples were
separated on 7% SDS-polyacrylamide gel with removal of GAG chains by
treatment with heparitinase and chondroitinase. The 281–2 antibody
recognized an approximately 65 kDa core protein. Lane 1: HLF, lane 2:
syndecan-1 transfectant (S2)human cells as in murine cells (Liebersbach and Sanderson, 1994).
Five syndecan-1 gene transfected clones, S1–S5 (lanes 5–9, Figure
5) were obtained after selection by geneticin and showed the
strong hybridization signals for mouse syndecan-1 mRNA at a size
of approximately 1.2 kb, which was consistent with the expected
size of the polyadenylated product of the mouse syndecan-1
expression vector, while the weak endogenous signals of human
syndecan-1 mRNA at 3.4 and 2.6 kb, as seen in the parental HLF
cells (lane 1, Figure 5) and vector-only transfected cells (lane 2,
Figure 5), were also obtained. The mRNA levels of transfected
mouse syndecan-1 gene at 1.2 kb (lanes 5–9, Figure 5) were much
higher than those of augmented human syndecan-1 gene in PR-39
transfectants (lanes 3 and 4, Figure 5).
To demonstrate that the syndecan-1 transfectants produced
syndecan-1 with heparan sulphate chains, we performed Western
blots of mouse syndecan-1 before and after removal of heparan
sulphate chains. The protein samples were separated on 5% SDS-
polyacrylamide gel without any treatments and then on 7% SDS-
polyacrylamide gel with removal of GAG chains treated with
heparitinase and chondroitinase. The 281–2 antibody recognized
the syndecan-1 protein as a smear without treatment (lane 2,
Figure 6A). Following removal of GAG chains from the protein,
the antibody specifically recognized a 65 kDa core protein in
syndecan-1 transfectants (lane 2, Figure 6B). These data indicate
that the syndecan-1 transfectants produced syndecan-1 with
heparan sulphate chains.
Syndecan-1 expression at cell surface in PR-39 or
syndecan-1 transfectants
To show levels of syndecan-1 at the cell surface, we performed
immunofluorescent analysis using an anti-human syndecan-1 anti-
body (BB4) which recognizes human syndecan-1 specifically, or
an anti-mouse syndecan-1 antibody (281–2) which recognizes
mouse syndecan-1 specifically. Using BB4 antibody, we observed
the higher immunofluorescence at the cell surface in PR-39 trans-
fectants (Figure 7A) than those of parental HLF, vector-only trans-
fectant and syndecan-1 transfectants (Figure 7B is a representative
of these three cell lines). However, syndecan-1 gene transfectants
showed a markedly high immunofluorescence at the cell surface
using 281–2 antibody (Figure 7D), while parental HLF, Mock and
PR-39 transfectants showed no immunofluorescence (Figure 7C is
a representative of these three cell lines).
Alteration of invasive activity, but not motile activity in
syndecan-1 transfectants
By using these transfectants, the invasive activity of the control
HLF cells, the vector-only transfected clone and the five
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Figure 7 Immunofluorescent analysis of syndecan-1 at cell surface in PR-39 or syndecan-1 transfectants. BB4 and 281–2 antibodies were used for human
and mouse syndecan-1 respectively. Using BB4 antibody, the higher immunofluorescence was observed at the cell surface in PR-39 transfectant (A) than that
of syndecan-1 transfectant (B). However, syndecan-1 gene transfectant showed a markedly high immunofluorescence at the cell surface using 281–2 antibody
(D), while PR-39 transfectant showed no immunofluorescence (C). A and C: PR-39 transfectant (P2), B and D: syndecan-1 transfectant (S2), A and B: human
syndecan-1, C and D: mouse syndecan-1. Scale bar, 15 mm
A B
C Dsyndecan-1 transfected clones were all assayed by the same proce-
dure used in the experiment for PR-39 gene transfectants. In the
experiment, the number of cells that invaded the filters was
counted after 24 h, as at 8 h, the interval used in PR-39 experi-
ment, the preliminary experiments had shown insufficient differ-
entiation of invasive activity between the syndecan-1 transfectants
and the control cells. All of the five syndecan-1 transfectants,
S1–S5 (lanes 3–7 in Figure 8A) showed a significant reduction of
invasive activity compared with that of the parental HLF cells and
the vector-only transfectant cells (lanes 1 and 2, Figure 8A).
Motile activity of the HLF cells, the vector-only transfected clone
and the five syndecan-1 transfectants was assayed by phagokinetic
tracks under the same conditions used in the PR-39 transfectants.
However, the S1–S5 clones (lanes 3–7, Figure 8B) showed no
difference of motile activity compared with the parental HLF cells
or the vector-only transfected clone (lanes 1 and 2, Figure 8B).
Effect of chlorate treatment on motile activity of PR-39
transfectants and syndecan-1 transfectants
Furthermore, we performed motility assay on type I collagen-
coated plates with or without chlorate treatment which prevents
the sulphation of glycosaminoglycan. Both of PR-39 and
syndecan-1 transfectants showed significant reductions of motile
activity on type I collagen-coated plates (lanes 3 and 4, Figure 9A)
compared with parental HLF and vector-only transfectants (lanes 1
and 2, Figure 9A). PR-39 transfectants treated with chlorate still
showed significant reductions of motile activity on type I collagen-
coated plates (lane 3, Figure 9B), while syndecan-1 transfectants
treated with chlorate almost returned to the same motile activity as
that of parental cells (lane 4, Figure 9B). Therefore, our results
convinced us that the role of PR-39 gene transduction in
suppressing tumour invasion is not restricted to the augmentation
of syndecan-1 expression.
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Figure 8 Invasive activity into type I collagen and motile activity assayed by
phagokinetic tracks of syndecan-1 transfectants. (A) Invasive activity was
assayed in vitro by type I collagen (150 mg)-coated 8-mm pore size filter of the
invasion chamber. The number of cells that invaded the filters after 24 h was
counted in six random microscope fields of ´200 magnification of the lower
filter surface to represent the invasive activity. All of the five syndecan-1
transfectants (lanes 3–7) showed significant reduction of invasive activity
compared with that of the HLF cells (lane 1) and the vector only transfectant
(lane 2). Lane 1: HLF cells, lane 2: a vector only transfectant, lanes 3–7:
syndecan-1 transfectants (S1–S5). *Values for invasive activities significantly
different from HLF (lane 1) (P < 0.001). †Values for invasive activities
significantly different from the vector-only transfectant (lane 2) (P < 0.05). 
(B) Motile activity of syndecan-1 transfectants was assayed by phagokinetic
tracks. After 48 h, phagokinetic tracks were visualized using dark-field
illumination in an inverted microscope at a magnification of 200´. The area
cleared of gold particles by cells represented motile activity and was
measured. Virtually no difference was observed among the five syndecan-1
transfectants (lanes 3–7) and the controls (lanes 1 and 2). Lane 1: HLF cells,
lane 2: a vector-only transfectant, lanes 3–7: syndecan-1 transfectants
(S1–S5)
Figure 9 Motility assay on type I collagen-coated plates with or without
chlorate treatment. (A) Both of PR-39 and syndecan-1 transfectants showed
significant reductions of motile activity on type I collagen-coated plates
without chlorate (lanes 3 and 4) compared with parental HLF and vector-only
transfectants (lanes 1 and 2). (B) PR-39 transfectants treated with chlorate
showed significant reductions of motile activity on type I collagen-coated
plates (lane 3), while syndecan-1 transfectants treated with chlorate showed
no significant reductions (lane 4). *Values for motile activities significantly
different from HLF (P < 0.001). †Values for motile activities significantly
different from the vector-only transfectant (P < 0.001). Lane 1: HLF, lane 2:
vector-only transfectant, lane 3: PR-39 transfectant (P2), lane 4: syndecan-1
transfectant (S2)Alteration of morphology and actin structure of PR-39
transfectant cells
As the motile activity of PR-39 transfected cells was reduced, we
next examined the morphology and actin structures of the cells
because of their bearing on cell motility. The phase-contrast
microscopic examinations of the parental HLF cells and the
vector-only transfectant revealed a flat form with short or long
spikes (Figure 10 A, B). On the other hand, PR-39 transfectants,
P1 and P2 formed more compact cells without spikes (Figure 10 C,
D), indicating that PR-39 gene transfection clearly influences the
cell morphology. Furthermore, actin filaments were stained with
rhodamine-conjugated phalloidin and actin structures were
observed with Laser Scanning Confocal Imaging System. The
parental HLF cells and the vector-only transfectant revealed
intense staining of fine microfilament bundles oriented parallel to
the long axes of the cells (Figure 11 A, B), whereas P1 and P2
revealed thin, short microfilament bundles or disorganization of
the microfilaments (Figure 11 C, D).
In contrast, syndecan-1 transfectants showed a flat form with
short or long spikes, which was indistinguishable from both the
parental HLF cells and the vector-only transfectant examined by
phase-contrast microscopy (data not shown). The actin structure of
S1–S5 clones revealed intense staining of fine microfilament
bundles oriented parallel to the long axes of the cells, which was
indistinguishable from that of both the parental HLF cells and the
vector-only transfectant (data not shown). Therefore, alteration of
cell morphology and actin structure might be important for the
suppression of motile activity in PR-39 transfectants; this would
be a new function of PR-39 in addition to its augmentation of
syndecan-1.
DISCUSSION
In this study, we obtained three findings:
1. PR-39 gene transduction to human hepatocellular carcinoma
cells induced syndecan-1 expression.
2. PR-39 gene transduction suppressed invasive and motile activ-
ities, while syndecan-1 gene transduction suppressed invasive
activity but not motile activity.
3. PR-39 gene transduction altered cell morphology and actin
structure, but syndecan-1 gene transduction did not.
Previously, we found that the expression of syndecan-1 was
reduced in human HCC with high metastatic potential and specu-
lated that syndecan-1 played an important role in the inhibition of
invasion and metastasis (Matsumoto et al, 1997). Accordingly, it is
assumed that the modification of this process by inducing
syndecan-1 may become a new strategy to inhibit these processes.
In 1994, Gallo et al attempted to identify soluble extracellular
factors that induce syndecan-1 expression from a pig skin wound
fluid, because the cutaneus wound environment is a potential
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Figure 10 Cell morphology of PR-39 transfectants. Morphology of the parental HLF cells (A) and a vector-only transfectant (B) examined by phase-contrast
microscopy was a flat shape with short or long spikes, but PR-39 transfectants, P1 and P2, revealed a more compact shape without the spikes (C and D). Scale
bar, 15 mm
A B
C Dsource of inductive factors (Gallo et al, 1994). They isolated a 4.7-
kDa protein that induced syndecan-1 in mouse NIH 3T3 fibro-
blasts and found that it was identical to PR-39 by amino acid
sequence analysis. In a preliminary experiment, we found that the
synthetic peptide of PR-39 augmented syndecan-1 mRNA expres-
sion in HLF cells in addition to in NIH 3T3 cells, although 
the amount required for syndecan-1 induction was more than 
10 mg ml–1, being rather high (unpublished observation). Because
the available amount of synthetic peptide was limited and pI of the
peptide was very basic due to the high content of proline and argi-
nine, and was easy to adhere non-specifically, we attempted to
transfect the PR-39 gene into HCC cells in order to obtain the
continuous expression of PR-39 in the cells. Two transfectants
with PR-39 gene, which were selected by geneticin and were
stably expressing PR-39, showed the induction of syndecan-1
mRNA but not syndecan-4 (Figure 2). The induction of syndecan-
1 at the cellular level in PR-39 transfectants was also confirmed by
immunofluorescent analysis using anti-human syndecan-1 anti-
body (Figure 7C).
These results support our assumption that PR-39 gene transduc-
tion works as a syndecan-1 inducer in HLF cells. An important
issue is what kind of mechanism is involved in the syndecan-1
induction by PR-39 gene transduction. It is reported that a biologi-
cally active segment of PR-39 is C-terminal proline-rich region.
However, our Western blot analysis mainly showed a precursor
form of PR-39 both in the cytoplasm and in the culture medium
(Figure 3), suggesting that PR-39 is mainly secreted as a precursor
form, not a clipped mature region of PR-39. Usually, mature PR-39
arises from the interaction with the serine protease of azurophilic
granules in neutrophils (Boman, 1995). Therefore the reason the
product of HLF cells overexpressing PR-39 gene is a precursor
form may be explained by the fact that HLF cells lack neutrophil
azulophilic granules and thus the precursor form is secreted extra-
cellularly without processing. However, it is noteworthy that the
PR-39 gene transduction works as a syndecan-1 inducer, which was
confirmed by the results including endogenous syndecan-1 induc-
tion and various changes of cell motilities and morphologies. The
possible explanations for this phenomenon are that immature PR-
39 directly functions as mature PR-39 or a very small amount of
mature PR-39 exists spontaneouly and functions, but can not be
detected by Western blot. Concerning the function of PR-39, Chan
and Gallo (1998) very recently postulated that extracellular PR-39
passed through cell membrane and binded intracellular binding
proteins (receptor). According to their assumption, intracellular
PR-39 or its precursor may also bind intracellular binding molecule
without excreting outside the cell. Very recently, we found several
intracellular proteins which interact with the chimeric protein
composed of PR-39 precursor and haemagglutinin, which was
made by transfection of chimaeric genes into HLF cells (not
published). Further studies are needed to clarify this issue.
PR-39 gene transduction alters invasive activity in hepatocellular carcinoma cells 401
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Figure 11 Actin structure of PR-39 transfectants. Actin structure was examined by staining of actin filaments using rhodamine-conjugated phalloidin. The HLF
cells (A) and a vector-only transfectant (B) revealed an intense staining of fine microfilament bundles oriented parallel to the long axes of the cells, whereas P1
and P2 revealed thin, short microfilament bundles or a disorganization of the microfilaments (C and D). Scale bar, 15 mmThe transfection experiments of the PR-39 gene and the
syndecan-1 gene, both of which showed significant suppression of
invasive activity in type I collagen-coated filter, demonstrated 
that the invasive activity of human HCC cells was modified by
syndecan-1 expression. The fact that syndecan-1 gene transfection
induced a functional syndecan-1 molecule was confirmed by SDS
polyacrylamide gel electrophoresis with or without heparitinase
treatment, by immunofluorescent analysis using anti-mouse
syndecan-1 antibody and by motile assays treated with sodium
chlorate, an inhibitor of sulphation of glycosaminoglycan. In
human B lymphoid cell line, the transfection of syndecan-1 gene
inhibited invasion into type I collagen by the cell binding
(Liebersbach and Sanderson, 1994). This observation also
supports one of our conclusions that cell-to-matrix interaction
through syndecan-1 and type I collagen is required to inhibit
tumour cell invasion. As pointed out by Liotta, the metastatic
cascade consists of a series of steps which include: leaving the
primary tumour, invading the local tissue, entering the circulation,
arresting at the distant vascular bed, extravasating into the target
organ interstitium and parenchyma, and proliferating as a
secondary colony (Liotta et al, 1986, 1991). Among these steps,
tumour cell invasion is one of the most important (Goyette et al,
1992; Dickson et al, 1996; Effert et al, 1996). Our results using the
transfection of PR-39 gene to tumour cells showed that the induc-
tion of syndecan-1 by PR-39 could result in the inhibition of
tumour cell invasion.
In addition to the function of PR-39 that can induce syndecan-1
expression, we found another effect of PR-39 gene transduction:
PR-39 gene transfectants showed alterations of motile activity and
actin structure not observed in syndecan-1 gene transfectants.
Furthermore, the motile activities of PR-39 transfectants were not
affected by chlorate treatment, suggesting strongly that PR-39 has
more functions than syndecan-1 induction. Two possible mecha-
nisms were evolved for the alteration of cell motility: one was an
involvement of a special class of enzymes called motor proteins
walking or sliding along a microfilament or a microtubule; the
other was the changes of cell shape which resulted from the
polymerization and assembly of actin (Stossel, 1993). The latter
mechanism seems to be more likely in the present case, because
alterations of motile activity and actin structure occurred simulta-
neously in the PR-39 gene transfectants. Thus, it is concluded that
PR-39 functions as a modifier of motile activity and actin struc-
ture, possibly through association with the proteins which control
actin polymerization and assembly of actin filaments, such as
actin-cross-linking proteins, small actin-binding proteins, actin-
severing proteins, actin-capping proteins or small GTP-binding
proteins. Moreover, new functions of PR-39 have been reported
that it inhibits phagocyte NADPH oxidase activity of pig
neutrophils by binding to Src homology 3 (SH3) domains of
p47phox (Shi et al, 1996) and that PR-39 binds and affects a SH3-
containing signal transduction protein, P130Cas (Chan and Gallo,
1998). Therefore, we expect that PR-39 may bind to SH3 domain
of various intracellular proteins based on two previous observa-
tions: (i) proline-rich motifs have an ability to bind to SH3
domains (Yu et al, 1994; Pawson, 1995); (ii) PR-39 has five
repeats of the proline-rich motif, PXXPPXXP (Storici and Zanetti,
1993), whose prototype is Sos, an activator of the ras guanine
nucleotide exchange protein (Gout et al, 1993; Musacchio et al,
1994). Thus, the alteration of actin structure caused by PR-39 gene
transduction might result from the binding of the proline-rich
region of PR-39 to SH3 domain of some protein associated with
polymerization or assembly of actin filaments, or intracellular
signalling. Further studies are needed to clarify this point.
It is also important to clarify how PR-39 induces syndecan-1
expression at mRNA level in HCC cells. A number of mechanisms
of syndecan-1 synthesis have been reported in different tissues: a
transcriptional regulation (Elenius et al, 1992), post-transcriptional
regulation (Sanderson et al, 1992; Vainio and Thesleff, 1992;
Yeaman and Rapraeger, 1993) and post-translational regulation
(Sanderson and Bernfield, 1988). In NIH 3T3 cells, the combina-
tion of basic fibroblast growth factor (bFGF) and transforming
growth factor b (TGF-b) at high concentrations increased
syndecan-1 expression at a transcriptional level (Elenius et al,
1992). In our experiment, syndecan-1 was induced both at mRNA
and protein levels, suggesting that a transcriptional or a post-
transcriptional regulation should be considered. However, an alter-
ation of mRNA stability of syndecan-1, which is a major cause of
post-transcriptional regulation, has not been reported. To assess
the transcriptional regulation of syndecan-1, the sequence
upstream of the first exon of syndecan-1 gene was investigated
and found to have a promoter activity; the sequence displays an
array of consensus transcription factor binding sites including
MyoD (E box), NF-kB, Spl (GC box) and TATA and CAAT boxes
(Hinkes et al, 1993). These observations suggest an association of
the signals of bFGF and TGF-b with the promoter activity of
syndecan-1 gene. Therefore, PR-39 may also be involved directly
or indirectly in the interaction with transcription factors which
bind to the promoter sites of syndecan-1 gene or with the signal
transduction pathways which are triggered by bFGF and TGF-b.
In conclusion, PR-39 could be a candidate gene to establish a
new strategy to inhibit the metastasis of tumour cells because of
the unique functions including the induction of syndecan-1,
suppression of invasive and motile activities, and change of actin
structure.
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